{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-298644","form_type":"8-K","ticker":"CPRX","cik":"0001369568","company_name":"CATALYST PHARMACEUTICALS, INC.","filed_at":"2023-12-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.777783+00:00","generated_at":"2026-06-07T10:26:17.520979+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Catalyst partner DyDo submits NDA in Japan for FIRDAPSE; milestone payment triggered","bullets":["DyDo Pharma submitted NDA to PMDA for FIRDAPSE (amifampridine) 10 mg for LEMS in Japan.","Submission based on favorable interim data after six months of the safety-phase registration study.","Upon acceptance of NDA filing, Catalyst due JPY 200M (~$1.4M USD) milestone payment from DyDo.","Territorial rights automatically expand to Asia, Central/South America; plans underway for global partnerships.","PMDA review period expected to be a minimum of nine months from submission date."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-298644","json":"https://secwatch.observer/filing/0001193125-23-298644.json","markdown":"https://secwatch.observer/filing/0001193125-23-298644.md","text":"https://secwatch.observer/filing/0001193125-23-298644.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1369568/000119312523298644/0001193125-23-298644-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1369568/000119312523298644/d676830d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T10:26:17.520979+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}